Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival.

Roman M ShapiroHaesook T KimRémy DuléryDeborah LineyHeather M GarrityKevin M PanaroChloe AuCasey GervaisJessica S LittleVincent T HoCorey S CutlerJohn KorethMahasweta GooptuJoseph H AntinAmar H KelkarRizwan RomeeCatherine J WuJerome RitzRobert J SoifferSarah Nikiforow

Published in: Blood advances (2024)

SCB can restore hematopoiesis in the majority of patients, particularly for those with poor graft function in whom there is no active infection at infusion.

Keyphrases

stem cells
end stage renal disease
ejection fraction
newly diagnosed
low dose
peritoneal dialysis
prognostic factors
combination therapy
free survival
patient reported